A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Abstract Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. Methods Study design: COMBIVAS is a randomised, double-blind, placebo-controlled...

Full description

Bibliographic Details
Main Authors: Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C.O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones, on behalf the COMBIVAS investigators
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Trials
Subjects:
ANCA
Vasculitis
Rituximab
Belimumab
Online Access:https://doi.org/10.1186/s13063-023-07218-y

Similar Items

Similar Items